SCHEMBL14739736

SCHEMBL14739736

CC(=O)c1cc(C#N)ccc1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
NOS3 P29474 2/20 0.39
NOS1 P29475 2/20 0.39
TMPRSS4 Q9NRS4 1/20 0.38
KMT2A Q03164 4/20 0.37
KDM4E B2RXH2 3/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
GFER P55789 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
DYRK1A Q13627 1/20 0.37
MEN1 O00255 3/20 0.37
GAA P10253 1/20 0.37
USP2 O75604 1/20 0.36
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36
PKM P14618 1/20 0.36
APEX1 P27695 1/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL634467 0.83 KDM4E (0.57) ALDH1A1MAPTKMT2AKDM4EGFER
SCHEMBL2312770 0.83 IKBKB (0.49) ALDH1A1MAPTKMT2AKDM4ECA1
SCHEMBL11573503 0.82 SETDB1 (0.39) ALDH1A1MAPTTMPRSS4KMT2AKDM4E
SCHEMBL23013861 0.81 NOS3 (0.39) ALDH1A1NOS3NOS1KDM4ECA2
SCHEMBL18534911 0.81 LRRK2 (0.41) ALDH1A1NOS3NOS1KDM4ECA1
SCHEMBL2033094 0.81 BRAF (0.42) ALDH1A1MAPTTMPRSS4KMT2AKDM4E
SCHEMBL9043331 0.81 RAB9A (0.42) ALDH1A1MAPTKMT2AKDM4ECA1
SCHEMBL4842734 0.81 ALDH1A1 (0.57) ALDH1A1MAPTKDM4ERXFP1GAA
SCHEMBL26561341 0.79 FFAR1 (0.42) ALDH1A1MAPTTMPRSS4KMT2AKDM4E
SCHEMBL311893 0.79 TMPRSS4 (0.52) ALDH1A1MAPTTMPRSS4CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034122-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2025-01-30 US disclosed
EP-4441044-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2024-10-09 EP disclosed
CN-118302422-A Substituted N-cyanopyrrolidines having activity as USP30 inhibitors 特殊治疗有限公司 2024-07-05 CN disclosed
WO-2023099561-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2023-06-08 WO disclosed
WO-2023099561-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2023-06-08 WO disclosed
US-20130059924-A1 PHOTOSTABILISERS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034122-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS USP30, USP47, USP1 ALDH1A1 707/4885MAPT 4262/4885NOS3 461/4885
US-20130059924-A1 PHOTOSTABILISERS ALDH1A1, ALDH18A1, ALDH1A2 ALDH1A1 1/4885MAPT 362/4885NOS3 3012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.